Month: November 2024

Managed Facility Solutions’ Haynes Dallas Selected as a Best CEO Awards Nominee by the Austin Business Journal

The full-service facility management company celebrated CEO Haynes Dallas who was among a select group of business owners that were recognized for their innovative leadership by the Austin Business Journal.

Managed Facility Solutions is pleased to share that Haynes Dallas was selected as a nominee for the Austin Business Journal (ABJ) 2024 Best CEO Awards. A nomination by the ABJ for the Best CEO Awards is recognition that honors business leaders who have exhibited innovation, supported progression and made a positive difference in the Austin community. 

Mr. Dallas heads the Logistics and Supply Chain division of Managed Facility Solutions while also overseeing the Operations, IT, Finance, Sales and Marketing teams at both the Austin location and the company headquarters in San Jose, CA. Mr. Dallas draws upon a wide array of knowledge and experience in law, economics and business management that is grounded by strong values. His commitment to sustainability has stood out and made Managed Facility Solutions an industry leader in responsible waste disposal, particularly the disposal of e-waste. 

Eighty CEOs from around the Austin business community were nominated for awards that are segmented into nine categories based on company size and type:  

  • Micro Company 
  • Small Company 
  • Medium Company 
  • Large Company 
  • Extra Large Company 
  • Public Company 
  • Nonprofit 
  • Startup 
  • Market Leader

With a total of 65 employees, Managed Facility Solutions is considered a medium size business. The company’s workforce has grown during Mr. Dallas’ time as CEO. His strategic vision and commitment to excellence have been instrumental in driving MFS’s success and enhancing the company’s reputation within the industry as it expands into new markets.

“Haynes Dallas is more than a leader. He’s a visionary who has transformed MFS
 into a thriving and successful organization. Haynes deserves the recognition
 because he makes all his employees feel valued and appreciated,” said Jaimee Tolentino, an Executive Assistant at Managed Facility Solutions. 

Managed Facility Solutions was established in San Jose 40 years ago, and choose to expand its successful operation in Austin during 2020. Despite the Covid-19 pandemic, Mr. Dallas was a steady steward and MFS remained profitable. All this while enhancing employee benefits, hiring new leadership team members, and consistently providing pay raises above the national average.

As a CEO, Mr. Dallas emphasizes success that is achieved through collective effort, believing that everyone’s contribution is essential. In addition to collaboration that fosters a strong sense of unity within the organization, employees are encouraged to seek new knowledge and skills. Providing support for employees to expand their capabilities has created a culture of innovation and growth that’s a direct reflection of Mr. Dallas’ leadership.

The Best CEO award winners were announced during a reception on October 16th at the Hotel Van Zandt in Austin, TX. The ceremony attendees included the nominees, judges, past winners and leaders in the Austin business community.  

2024 Best CEO Award Nominee: Managed Facility Solutions CEO Haynes Dallas 

To learn more about Managed Facility Solutions and its relocation services, please visit www.mfs.team. A full list of the nominees for the Austin Business Journal 2024 Best CEO Awards can be found on the Austin Business Journal website. 

About MFS

Managed Facility Solutions (MFS) has been a support system for businesses that are moving, relocating and reconfiguring their facilities since 1984. As a full-service facility management company, Managed Facility Solutions offers a wide selection of specialized services that meet the needs of modern corporate relocations involving data centers, IT systems, technologically advanced office equipment and e-waste disposal.  

Media Contact
Company Name: Managed Facility Solutions
Contact Person: JAIMEE TOLENTINO
Email: Send Email
Phone: 512-893-8712
Country: United States
Website: https://www.mfs.team/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Managed Facility Solutions’ Haynes Dallas Selected as a Best CEO Awards Nominee by the Austin Business Journal

Hearn Landscape Expands Services to Newnan, GA: Elevating Landscape Solutions with Professional Expertise and Local Insights

“The town of Newnan, GA”
Hearn Landscape, a leading landscaping company in Georgia, is expanding its services to Newnan, GA, providing expert lawn care, sod installation, irrigation, outdoor lighting, and seasonal landscaping tailored to the local environment. This expansion is supported by a strategic partnership with SevenWired, a digital marketing agency specializing in local SEO and online branding.

Newnan, GA – November 6, 2024 – Hearn Landscape, a trusted provider of comprehensive landscaping services, is proud to announce its expansion to Newnan, GA, a move aimed at bringing its high-quality lawn care, irrigation, and landscape design services to more communities in Georgia. Known for transforming properties with a meticulous approach to landscaping and a dedicated team, Hearn Landscape is now ready to serve the beautiful landscapes of Newnan, offering customized solutions that cater to both residential and commercial needs. This expansion is supported by the expertise of SevenWired, a leading digital marketing agency, which has been instrumental in crafting a strategic, localized marketing approach for Hearn Landscape’s launch in Newnan.

As one of Georgia’s premier landscaping companies, Hearn Landscape has built a strong reputation for attention to detail, reliability, and a commitment to customer satisfaction. Founded on the principles of quality craftsmanship and environmental stewardship, the company has helped countless homeowners and business owners achieve lush, healthy lawns and well-designed outdoor spaces tailored to their unique needs.

Serving Newnan with Specialized Landscaping Solutions

Hearn Landscape’s expansion to Newnan comes as a response to the growing demand for reliable and professional landscaping services in the area. The company provides a variety of services, including but not limited to sod installation, plant selection, irrigation, lighting, and ongoing maintenance — all backed by an industry-leading warranty program. The team’s expertise spans the full spectrum of landscaping needs, from soil health assessments to creating vibrant, seasonal designs that thrive in Newnan’s climate.

With this expansion, Hearn Landscape aims to support Newnan’s residents and businesses in enhancing their outdoor spaces. The team understands the specific challenges of landscaping in Georgia’s diverse climate and soil types, enabling them to provide customized solutions that prioritize both aesthetics and sustainability. Residents and businesses can now experience Hearn Landscape’s renowned service firsthand by visiting the company’s Newnan location on Google Maps.

A Team with Passion and Precision

The success of Hearn Landscape is driven by a skilled team passionate about creating beautiful outdoor spaces. Each team member brings specialized expertise to the table: Stewart leads with a keen eye for plant selection and creative vision, while Matthew heads the crew with precision and attention to detail. Debi manages client communications, ensuring that each customer has a smooth and satisfactory experience. Together, they have made Hearn Landscape a name synonymous with high standards in landscaping, from planning to execution.

With a commitment to environmentally friendly practices, Hearn Landscape incorporates eco-conscious methods into its projects. The team prioritizes native plants and sustainable materials whenever possible, ensuring that each landscape not only looks stunning but also supports local biodiversity and conserves resources. This approach aligns well with the values of Newnan’s residents, who are increasingly aware of the importance of sustainability in their community.

Partnership with SevenWired: Enhancing Visibility and Reach in Newnan

The strategic partnership with SevenWired, a full-service digital marketing agency, has played a crucial role in Hearn Landscape’s expansion into Newnan. With a dedicated focus on optimizing Hearn Landscape’s visibility and reach in the Newnan area, SevenWired has crafted a localized digital marketing strategy that reflects Hearn Landscape’s commitment to quality and customer satisfaction. This collaboration ensures that Newnan residents can quickly and easily find Hearn Landscape’s services online, allowing for seamless connections with potential clients in need of landscaping expertise.

As an experienced digital marketing agency, SevenWired specializes in helping local businesses thrive by implementing effective SEO strategies, content creation, and customer engagement tactics. Through their targeted efforts, SevenWired has amplified Hearn Landscape’s online presence in Newnan, creating brand awareness that resonates with the local community. More information about SevenWired’s digital marketing services in Newnan, GA, can be found on their website.

Services Tailored to Newnan’s Unique Landscape

Understanding the unique aspects of Newnan’s environment, Hearn Landscape has tailored its service offerings to address common local challenges, such as soil composition, seasonal variations, and specific plant species that thrive in the region. Hearn Landscape’s services include:

  • Sod Installation: Hearn Landscape provides expert sod installation, selecting varieties that thrive in Newnan’s soil and weather conditions. From prepping the ground to ensuring proper irrigation, the team guarantees a seamless installation process with a focus on long-term lawn health.

  • Plant Selection and Seasonal Design: Stewart, a specialist in horticulture and landscape design, brings extensive knowledge in plant selection. His selections prioritize both beauty and resilience, ensuring that each plant contributes to a balanced ecosystem within the landscape.

  • Irrigation and Water Management: Proper watering is crucial for maintaining a healthy landscape, especially in Georgia’s warmer months. Hearn Landscape offers comprehensive irrigation solutions that conserve water while providing optimal hydration for plants.

  • Outdoor Lighting: Hearn Landscape’s lighting solutions highlight landscape features while providing functional lighting for walkways and outdoor spaces. These installations are designed to enhance the property’s appearance while increasing safety and usability.

Building Long-Term Relationships with the Newnan Community

Hearn Landscape is not just another landscaping company entering Newnan. The company aims to become a part of the community, building lasting relationships with residents, homeowners, and business owners alike. By prioritizing communication and transparency, the Hearn Landscape team ensures that every client feels valued and involved in the landscaping process. Debi, who oversees client communication, works closely with each client to address their specific needs and maintain open lines of communication throughout each project.

Hearn Landscape’s move into Newnan also reflects its commitment to giving back to the community. The company plans to participate in local events and support neighborhood initiatives that promote environmental sustainability and beautification efforts. This engagement reinforces Hearn Landscape’s dedication to Newnan, ensuring that the company remains a supportive and valued community partner.

A Vision for Growth with Quality and Integrity

As Hearn Landscape embarks on this new chapter in Newnan, the company remains committed to its foundational values of quality, integrity, and a customer-centered approach. Every project is approached with the same dedication to detail and excellence that has made Hearn Landscape a trusted name in landscaping across Georgia. Through continuous training and adherence to industry best practices, the Hearn Landscape team ensures that their services remain innovative, efficient, and responsive to each client’s evolving needs.

SevenWired has been instrumental in promoting Hearn Landscape’s brand within Newnan, utilizing effective SEO and digital marketing techniques that make Hearn Landscape’s services easy to find and accessible to the community. For more about how SevenWired has helped Hearn Landscape reach a new audience, you can explore their digital marketing solutions tailored for Newnan businesses.

Experience the Hearn Landscape Difference

Newnan residents and business owners now have the opportunity to transform their outdoor spaces with the trusted expertise of Hearn Landscape. Whether you’re looking to create a vibrant garden, install sod for a lush green lawn, or need professional irrigation solutions, Hearn Landscape’s team is ready to provide reliable, quality service.

About Hearn Landscape

Hearn Landscape is a full-service landscaping company providing top-tier landscape design, sod installation, irrigation, lighting, and seasonal maintenance across Georgia. With a commitment to excellence and sustainability, Hearn Landscape combines experience with a deep understanding of the local environment to deliver custom outdoor spaces that enhance property value and curb appeal.

About SevenWired

SevenWired is a digital marketing agency specializing in helping businesses grow through tailored SEO, content marketing, and online branding strategies. With a focus on local businesses, SevenWired works closely with clients to boost visibility and drive growth through innovative, results-oriented digital solutions. To learn more about their services, visit SevenWired’s website.

For media inquiries, please contact:

Media Contact
Company Name: Hearn Landscape- Newnan
Contact Person: Sam Hearn
Email: Send Email
Phone: (404)550-8360
Address:860 Smokey Rd
City: Newnan
State: Georgia
Country: United States
Website: https://hearnlandscape.com/location/newnan-ga/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hearn Landscape Expands Services to Newnan, GA: Elevating Landscape Solutions with Professional Expertise and Local Insights

Closed System Transfer Devices Market Exploring Future Growth Potential, New Developments, Company Performance and Forecast 2029

“North America accounted for the largest share of closed system transfer devices market. Owing to the continuous development and introduction of advanced CSTD technologies along with enhanced safety, efficiency, and user experience contributes to the high adoption rates of CSTDs in this region.”
Browse 414 market data Tables and 58 Figures spread through 343 Pages and in-depth TOC on “Closed System Transfer Devices Market by Type (Membrane-to-Membrane, Needleless), Technology, Component (Vial Access Device, Male luer, Bag Spike, Female Component), End User (Hospitals & Clinics, Oncology Center) – Global Forecast to 2029

Closed System Transfer Devices market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a latest report published by MarketsandMarkets™.

One major driver is the growing concerns about the safety of healthcare workers, particularly with regard to exposure to dangerous medications during cancer treatment. The implementation of CSTDs is further required by more stringent regulations requiring safe handling methods. The need for such devices is also fueled by the growing incidence of illnesses like cancer and the growing application of powerful medications in customized medicine. The adoption of these products in hospitals and oncology centres is, however, somewhat hampered by the initial investment needed to implement CSTDs, resistance to change within organisations, the healthcare industry’s historically slow adoption of new technologies, and regulatory complexities and compliance requirements.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251802928

NIOSH defines a Closed System Drug-Transfer Device (CSTD) as “a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of the hazardous drug or vapor concentrations outside the system”.

By closing mechanism, the CSTD market is segmented into Luer-lock systems, color-to-color alignment systems, click-to-lock systems, and push-to-turn systems. In 2023, the Luer-lock systems segment accounted for the highest share of the market. The segment accounted for the highest share in the market due to factors like standardization and compatibility, ease of use, cost-effectiveness and wide range of application.

Based on type, the CSTD market is segmented into membrane-to-membrane systems and needleless systems. In 2023, the membrane-to-membrane systems segment accounted for the largest share in the CSTDs market. Membrane-to-membrane systems offer a highly effective and reliable method for transferring hazardous drugs while maintaining a closed environment, thereby minimizing the risk of exposure to healthcare workers and patients.

Based on technology, the CSTDs market is segmented into diaphragm-based devices, compartmentalized devices, and air cleaning/filtration devices. In 2023, the diaphragm-based devices segment accounted for the largest share of the market. These devices are often perceived as cost-effective options compared to other types of CSTDs, making them attractive to organizations looking to maximize value without compromising on safety. Additionally, diaphragm-based CSTDs are relatively easy to use and require minimal training, reducing the learning curve for healthcare professionals and facilitating widespread adoption.

Based on components, the CSTDs market is segmented into vial access devices, bag spikes, male luers, female components and other components. In 2020, the female component segment accounted for the largest share of the market. female components are widely recognized for their compatibility with various types and sizes of drug vials, offering versatility and flexibility in drug handling processes. Furthermore, advancements in female component technology have led to the development of innovative designs that prioritize ease of use, reliability, and user comfort, further enhancing their appeal to healthcare facilities.

Based on end users, the market is segmented into hospitals & clinics, oncology centers, and other end users. In 2023, hospitals & clinics accounted for the largest share of the CSTDs market. The large share and high growth of this segment are mainly due to the strong financial capabilities of hospitals for purchasing high-priced CSTDs, the large cancer patient pool, and the need to comply with regulatory guidelines.

In 2023, North American region accounted for the largest share of the closed system transfer devices market. This is due to the presence of many leading manufacturers based in North America, high prevalence of cancer, easier access to advanced technologies, and strong awareness of the benefits of CSTDs for protecting healthcare professionals from exposure to hazardous drugs.

Additionally, the Asia-Pacific region is anticipated to have the highest CAGR of 17.0% during the forecast period. This growth is attributed to the increasing government investments in healthcare, especially in countries like China, India, and Japan, advancements in the healthcare sector, increasing healthcare infrastructure and surge in the prevalence of chronic diseases requiring chemotherapy and other hazardous drug treatments.

Buy a Closed System Transfer Devices Industry Report (250 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=251802928

Closed System Transfer Devices market major players covered in the report, such as:

  • Becton, Dickinson and Company (US)
  • ICU Medical (US)
  • B Braun Melsungen (Germany)
  • Simplivia Healthcare (Israel)
  • Corvida Medical (US)
  • Yukon Medical (US)
  • JMS (Japan)
  • Equashield (US)
  • Corning Incorporated (US)
  • Terumo Corporation (Japan)
  • Cardinal Health (US)
  • Eraser Medical (Turkey)
  • Baxter International (US)
  • West Pharmaceuticals Services (US)
  • CODAN Medizinische Geräte GmbH & Co KG (Germany)
  • Victus (US)
  • Caragen (Ireland)
  • Vygon SA (US)
  • Practivet (US)
  • Insung Medical (South Korea)
  • and Among Others

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=251802928

The research report categorizes closed system transfer device market into the following segments:

By Closing Mechanism

  • Luer Lock System
  • Push-to-Turn System
  • Click-to-Lock System
  • Color-to-Color alignment System

By Type

  • Membrane-to-Membrane systems
  • Needleless Systems
  • By Component
  • Vial access components
  • Male Luers
  • Bag Spikes
  • Female Components
  • Other Components

By Technology

  • Diaphragm-based devices
  • Compartmentalized devices
  • Air cleaning/filtration devices

By Country

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Colombia
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • Rest of Middle East and Africa

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=251802928

Key Market Stakeholders:

  • CSTD Manufacturers
  • CSTD Suppliers & Distributors
  • Original Equipment Manufacturers (OEMs)
  • Hospitals and Clinics
  • Oncology Centers
  • Medical Device Research and Consulting Firms
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Government Associations
  • Market Research and Consulting Firms
  • Venture Capitalists and Investors

Report Objectives:

  • To define, describe, and forecast the closed system transfer devices (CSTDs) market based on closing mechanism, type, component, technology, end user, and region  
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall closed system transfer devices market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the closed system transfer devices market in five regions, namely, North America (US and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe)), the Asia Pacific (Japan, China, India, Australia & New Zealand, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, Colombia, and Rest of Latin America), and the Middle East and Africa (GCC countries, and Rest of Middle East and Africa)  
  • To analyze the impact of the economic recession on the growth of the closed system transfer devices market
  • To strategically profile the key players in the global market and comprehensively analyze their core competencies
  • To track and analyze competitive developments, such as product launches, expansions, acquisitions, partnerships, collaborations, and agreements, of the leading players in the market

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/closed-system-transfer-device-market-251802928.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Closed System Transfer Devices Market Exploring Future Growth Potential, New Developments, Company Performance and Forecast 2029

Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

DelveInsight’s ‘Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast–2034’ report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular Degeneration Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Macular Degeneration Market Size

 

Key Takeaways from the Age-related Macular Degeneration Market Report

  • In November 2024:- Genentech Inc.- The main objective of the study is evaluation of the safety and tolerability of OpRegen – Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
  • In November 2024:- Stealth Bio Therapeutics Inc.- The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
  • In November 2024:- 4D Molecular Therapeutics- A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration. This Phase 1/2 trial is a prospective, multicenter, Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment who have demonstrated a clinical response consistent with anti-VEGF activity. The trial consists of Dose Escalation, Dose Expansion, Steroid Optimization and Population Extension Cohorts.
  • In the year 2022, the total prevalent cases of AMD were approximately 52,684,880 in the 7MM, which might increase at a decent CAGR by 2034.
  • The US accounted for approximately 17,688,550 prevalent cases of AMD in the year 2022.
  • The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
  • Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.

 

Delve deep into the Age-related Macular Degeneration Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Macular Degeneration Market Forecast. Click here to shape the future @ Age-related Macular Degeneration Epidemiology Insights

  

Age-related Macular Degeneration Epidemiology Insights

  • Total Age-related Macular Degeneration Prevalent Cases
  • Total Age-related Macular Degeneration Age-specific Cases
  • Total Age-related Macular Degeneration Diagnosed Prevalent Cases
  • Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
  • Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
  • Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

 

Navigate the complexities of the Age-related Macular Degeneration Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Macular Degeneration Market Forecast. Click here to get more insights @ Age-related Macular Degeneration Prevalence

 

Age-related Macular Degeneration Market Insights

Age-related Macular Degeneration is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss.

 

Age-related Macular Degeneration Treatment Landscape

The best available treatment for AMD was photodynamic therapy—in which an intravenous drug (injected into a vein) and laser were used to seal off leaking blood vessels. Past studies have found that just 1 year after diagnosis, less than 15% of patients given this therapy alone retain 20/40 vision, and up to 40% decline to 20/200 vision. However, advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function.

 

Age-related Macular Degeneration Market Size

According to the DelveInsight analysis, the United States accounted for the highest market size, with approximately 50% of the market share of Dry age-related Macular Degeneration (AMD) as compared to other countries of the 7MM in the year 2022. The Age-related Macular Degeneration market size of the 7MM is anticipated to increase in the forecast period due to expected launch of emerging therapies in the 7MM.

 

Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Macular Degeneration Market Forecast. Click here @ Age-related Macular Degeneration Market Drivers and Barriers

 

Age-related Macular Degeneration Therapies and Companies

  • Eylea (aflibercept): Regeneron Pharmaceuticals
  • Beovu(brolucizumab): Novartis
  • Lucentis (ranibizumab): Roche
  • Vabysmo (faricimab): Roche
  • Susvimo (ranibizumab): Roche

 

Age-related Macular Degeneration Drug Market

The overall Age-related Macular Degeneration (AMD) Market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2024–2034).

 

Scope of the Age-related Macular Degeneration Market Report

  • Coverage- 7MM
  • Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
  • Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
  • Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
  • Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Age-related Macular Degeneration Market Access and Reimbursement

 

Gain a strategic edge in the Age-related Macular Degeneration Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Macular Degeneration Market Forecast. Click here to lead in advancements @ Age-related Macular Degeneration Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders’ Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

Disposable Contact Lenses Market to Hit $13.45 Billion by 2029, More than $4 Billion Opportunities in the Next 6 Years – Arizton

“Disposable Contact Lenses Market Research Report by Arizton”
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

According to Arizton’s latest research report, the global disposable contact lenses market is growing at a CAGR of 9.10% during 2023-2029.

          

Looking for More Information? Click: https://www.arizton.com/market-reports/disposable-contact-lenses-market

   

Report Scope:          

Market Size – Revenue (2029): $13.45 Billion              

Market Size – Revenue (2023): $7.98 Billion              

CAGR (2023-2029): 9.10%      

Historic Year:  2020-2022                  

Base Year: 2023                  

Forecast Year: 2024-2029                  

Market Segmentation: Usage Type, Material, Application, Design, Distribution Channel and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa  

 

Market Overview

In 2023, the United States dominated the North American disposable contact lenses market, holding a substantial share of the global market. The U.S. was the largest revenue contributor, driven by a growing number of contact lens users and a shift toward more convenient eye care solutions. This increase in demand for disposable contact lenses is linked to the rising prevalence of common eye conditions such as myopia, presbyopia, and astigmatism.

The Centers for Disease Control and Prevention (CDC) reported millions of contact lens wearers in the U.S. The use of daily disposable lenses has seen a steady rise, with prescription rates increasing over the past two decades. The growing popularity of disposable lenses is also driven by the need for easy and comfortable vision correction.

Myopia is particularly prevalent in the U.S., affecting a significant portion of the population. Over the past 30 years, the prevalence of myopia has increased dramatically. Additionally, presbyopia, which affects those aged 45 and older, is the most common eye condition in the country, with millions of individuals affected. Astigmatism, another condition treatable with disposable contact lenses, also impacts a large percentage of the U.S. population, further driving demand for these products. As a result, the disposable contact lens market in the U.S. is expected to continue growing.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/disposable-contact-lenses-market

 

Recent Vendor Activities

Bausch & Lomb (2024): One of the leading companies in the disposable contact lens industry, Bausch & Lomb, launched INFUSE for Astigmatism – a daily disposable contact lens designed to treat astigmatism, blurred vision, and dryness. This innovation enhances visual clarity and comfort for users with astigmatism.

Hubble Contacts (2023): An emerging player in the market, Hubble Contacts launched the SkyHy disposable contact lens, its first silicon hydrogel-based product. Designed for high oxygen flow to the eyes, it promotes optimal eye health. The SkyHy lens features low rigidity and a smart multi-curvature edge for improved lens stability.

CooperVision (2022): The Cooper Companies announced that its full range of silicon hydrogel 1-day contact lenses is now net plastic neutral. As part of their sustainability efforts, the company expanded its leadership in eco-friendly practices. Additionally, CooperVision’s MyDay Daily Disposable contact lenses joined the clarity-1 day portfolio, becoming the first net plastic neutral contact lens.

Johnson & Johnson (2022): The U.S. FDA approved Acuvue Theravision with Ketotifen, a daily disposable contact lens from Johnson & Johnson. This lens is the first drug-eluting disposable contact lens on the market, designed to treat allergic eye conditions while offering clear vision and comfort.

 

Market Competition Overview

The global disposable contact lenses market is highly fragmented, with some major players holding significant market share, while also offering considerable growth opportunities for new entrants. Although the market is dominated by well-established companies, there is a notable influx of smaller, innovative firms developing new disposable contact lenses and associated technologies.

Leading Companies Major players such as Alcon, Bausch + Lomb, Johnson & Johnson Vision Care, Inc., and The Cooper Companies, Inc. collectively account for more than 60% of the market share in the global disposable contact lenses market. These companies are actively expanding through acquisitions of smaller vendors, positioning themselves to maintain dominance by continually engaging in the development of advanced solutions.

Strategic Focus of Market Leaders To strengthen their market presence and capture a larger share, leading companies are focusing on a range of strategies. These include launching new products, increasing marketing and promotional activities, pursuing mergers and acquisitions, expanding market penetration, and collaborating with government entities. These efforts aim to enhance their product portfolios and distribution networks, thus improving their competitive edge in both domestic and international markets.

Geographical Reach and Product Innovation The dominant players in the market benefit from a wide geographical reach, offering a diversified portfolio of services and a strong focus on high-quality disposable contact lenses. Their ability to cater to both domestic and international markets enable them to maintain a competitive advantage.

Growing Competition from Emerging Companies In recent years, several emerging companies have entered the market, integrating advanced tools and technologies to improve product quality. This has intensified competition, as both established and new companies innovate to meet the evolving demands of consumers. Additionally, there has been a notable rise in mergers, acquisitions, and collaborations, further fueling competition and driving industry growth.

However, major companies currently lead the market, there is ample opportunity for new entrants and smaller players to thrive by capitalizing on innovation and strategic partnerships. The competitive landscape continues to evolve as companies work to enhance their market presence and meet the increasing demand for advanced disposable contact lens solutions.

 

Key Vendors

  • Alcon
  • Bausch + Lomb
  • Johnson & Johnson
  • The Cooper Companies
  • Ben Q Material
  • Carl Zeiss
  • MAXVUE VISION GROUP
  • St. Shine Optical Co Ltd.
  • Menicon Co. Ltd
  • HOYA Corporation
  • Ultravision
  • Visioneering Technologies, Inc.
  • Sensimed
  • Aqualens
  • SEED Co., Ltd.
  • Clerio Vision
  • Interejo Co. Ltd.
  • Hubble
  • Visco Vision

 

Segmentation & Forecast

  • Usage Type 

  • Daily Disposable or Dailies 

  • Frequent Replacement/ Planned or Extended Wear 

  • Material 

  • Silicone Hydrogel 

  • Hydrogel 

  • Applications 

  • Corrective 

  • Therapeutics 

  • Cosmetic 

  • Design 

  • Spherical 

  • Toric 

  • Multifocal 

  • Distribution Channel 

  • Retail Optical Stores 

  • Hospitals & Ophthalmology Clinics 

  • Online Stores 

  • Geography 

  • North America 

  • The US 

  • Canada 

  • APAC 

  • Japan 

  • China 

  • India 

  • South Korea 

  • Australia 

  • Europe 

  • Germany 

  • France 

  • The UK 

  • Spain 

  • Italy 

  • Latin America 

  • Brazil 

  • Mexico 

  • Argentina 

  • Middle East & Africa 

  • Turkey 

  • Saudi Arabia 

  • South Africa 

  • The UAE 

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the disposable contact lenses market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/disposable-contact-lenses-market

 

What Key Findings Will Our Research Analysis Reveal?        

What are the key drivers of the global disposable contact lenses market?

How big is the global disposable contact lenses market?

Which region shows the highest growth in the global disposable contact lenses market?

What is the growth rate of the global disposable contact lenses market?

Who are the major players in the global disposable contact lenses market?

  

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4530

  

Other Related Reports that Might be of Your Business Requirement        

Global Online Pharmacy Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/online-pharmacy-market-size-analysis

Global Body Contouring Devices Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/body-contouring-devices-market

 

Why Arizton?                                                   

100% Customer Satisfaction                                                   

24×7 availability – we are always there when you need us                                                   

200+ Fortune 500 Companies trust Arizton’s report                                                   

80% of our reports are exclusive and first in the industry                                                   

100% more data and analysis                                                   

1500+ reports published till date                                 

                      

Post-Purchase Benefit                                               

  • 1hr of free analyst discussion                                               
  • 10% off on customization                            

                     

About Us:                                                                                        

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                      

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                       

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                             

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/disposable-contact-lenses-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Disposable Contact Lenses Market to Hit $13.45 Billion by 2029, More than $4 Billion Opportunities in the Next 6 Years – Arizton

Galveston County Divorce Attorney Lacey Richmond Releases Article on Wives’ Entitlements in Texas Divorce Settlements

Galveston County divorce attorney Lacey Richmond (https://www.richmondpllc.com/what-is-a-wife-entitled-to-in-a-divorce-settlement/), of Richmond Law Firm, PLLC, provides critical insights for wives managing divorce settlements in Texas, where unique legal factors can significantly affect financial and custodial outcomes. Known for Texas’s distinctive community property laws, Lacey Richmond emphasizes the importance of understanding state laws on property division, financial support, and child custody to secure an equitable settlement.

Richmond’s recent article sheds light on the specific entitlements that wives should expect and negotiate for in a divorce settlement, with a focus on the critical elements of financial and custodial security. “Divorce is challenging for anyone, but for wives who may have left the workforce or made career sacrifices, pursuing fair financial and custody outcomes is essential to achieving stability in the years to come,” the Galveston County divorce attorney says. Through explanations of common terms and rights, Richmond aims to support wives through every stage of the divorce process, helping them secure a fair and just settlement.

In Texas, divorce proceedings consider both community and separate property, an approach with significant implications for asset division. As a Galveston County divorce attorney, Richmond underscores that Texas courts view community property — all assets acquired during marriage — as jointly owned, subject to an equitable split between spouses. Separate property, including pre-marriage assets or those acquired via inheritance or gift, remains with the original owner, a key distinction for wives concerned about their financial security. This legal framework, Richmond advises, necessitates a clear inventory of both marital and non-marital assets to prevent misclassification that could negatively impact a wife’s financial stability post-divorce.

Wives in Texas face unique financial changes during and after a divorce, and Richmond highlights several forms of financial support that may be available. Texas courts may award alimony to help one spouse — often the lower earner — maintain a lifestyle close to that enjoyed during the marriage. Richmond notes that alimony, or spousal support, is determined based on factors such as the marriage’s duration, each spouse’s financial capacity, and the wife’s current earning potential. “For many wives who have prioritized family over career, alimony can provide an essential bridge, allowing them to rebuild financial independence after divorce,” Richmond explains.

In addition to spousal support, child support is another critical area Richmond addresses. Texas mandates child support to cover essential expenses such as housing, education, and medical care, a financial obligation primarily assigned to the non-custodial parent. For wives serving as primary caregivers, understanding these support guidelines can be key to helping ensure their children’s well-being and adjusting to the new financial reality.

Custody is another complex factor in Texas divorces, and Richmond advises that the state favors joint managing conservatorship (JMC) to encourage shared parental responsibilities. JMC, however, can be challenging for wives concerned about continued contact with an ex-spouse, especially in cases where sole managing conservatorship (SMC) might be more appropriate. Richmond emphasizes that Texas custody determinations focus on the child’s best interest, weighing factors such as each parent’s capability, the child’s preferences, and the stability of each home environment.

Custody determinations impact not only parenting time but also access to key family assets, such as the marital home, which may be awarded to the primary caregiver to maintain continuity and stability for children. Richmond stresses that for many mothers, retaining the family home can be essential, creating a stable foundation for children in an otherwise disruptive time.

For wives involved in high-asset divorces, Richmond addresses the unique complex matter of dividing substantial assets such as businesses and pensions. Business interests can require valuation and decisions regarding buyouts or ownership restructuring, which can significantly affect a wife’s financial future. Pensions and retirement accounts, too, are assessed based on the marriage’s duration, often resulting in a division that offers long-term financial security to wives who may not have their own retirement accounts.

For wives going through a Texas divorce, Lacey Richmond’s legal insights offer a roadmap to securing a fair settlement and preserving financial stability. Richmond Law Firm, PLLC emphasizes compassionate representation and clear communication, assisting clients in understanding their rights and planning for their future.

About Richmond Law Firm, PLLC:

Richmond Law Firm, PLLC, based in Galveston County, Texas, can provide comprehensive legal services focused on family law and divorce. Led by attorney Lacey Richmond, the firm is dedicated to helping ensure that clients receive fair and supportive representation through each stage of divorce and family legal matters. Richmond Law Firm, PLLC prioritizes personalized support, helping clients manage divorce settlements, custody issues, and asset division in a way that secures their rights and supports their future.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=m8WmdiTeCbQ

GMB: https://www.google.com/maps?cid=5010991770395509709

Email and website

Email: lacey@richmondpllc.com

Website: https://www.richmondpllc.com/

Media Contact
Company Name: Richmond Law Firm, PLLC
Contact Person: Lacey Richmond
Email: Send Email
Phone: (281) 992-1600
Address:211 E Parkwood Dr UNIT 201
City: Friendswood
State: Texas 77546
Country: United States
Website: https://www.richmondpllc.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Galveston County Divorce Attorney Lacey Richmond Releases Article on Wives’ Entitlements in Texas Divorce Settlements

Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Hereditary Angioedema Market is an evolving segment of the global healthcare landscape, driven by the increasing Hereditary Angioedema prevalence of the disorder and the continuous development of innovative treatment options. The Hereditary Angioedema market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

 

Discover Key Insights into the Hereditary Angioedema Market with DelveInsight’s In-Depth Report @ Hereditary Angioedema Market Size

 

Key Takeaways from the Hereditary Angioedema Market Report

  • In November 2024:- Octapharma- Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema Attacks
  • In November 2024:- CSL Behring- A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age. The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
  • In November 2024:- Pharvaris Netherlands B.V.- This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
  • In 2023, the diagnosed prevalent population of HAE was found to be ~7,000 cases in the US.
  • With type I Hereditary Angioedema (HAE) occupying the maximum diagnosed patient pool in the US, this condition had ~5,500 diagnosed cases in 2023.
  • DelveInsight’s analysts have estimated that there were ~1,000 cases diagnosed for the age group 17 to below 65 years in 2023.
  • The leading Hereditary Angioedema Companies such as KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
  • Promising Hereditary Angioedema Therapies such as KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others

 

Stay ahead in the Hereditary Angioedema Therapeutics Market with DelveInsight’s Strategic Report @ Hereditary Angioedema Market Outlook

 

Hereditary Angioedema Epidemiology Segmentation in the 7MM

  • total Hereditary Angioedema diagnosed prevalent population
  • Hereditary Angioedema type-specific
  • Hereditary Angioedema gender-specific
  • Hereditary Angioedema age-specific
  • Hereditary Angioedema site-specific cases

 

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Prevalence

 

Hereditary Angioedema Marketed Drugs

  • Takhzyro: Takeda

Takhzyro (Lanadelumab; DX-2930) is the first of its kind, a fully human monoclonal antibody (mAb) that binds and inhibits the activity of plasma kallikrein, an enzyme that is uncontrolled in people with HAE. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin. This potent vasodilator increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, it led to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Lanadelumab decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE. Lanadelumab is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology and available as subcutaneous formulation.

  • Firazyr: Shire/Takeda

Firazyr (Icatibant) is a selective, competitive bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. The dysfunctional C1-esterase-inhibition leads to bradykinin production. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor, with an affinity similar to bradykinin, and thereby treats the clinical symptoms of an acute, episodic attack of HAE. Firazyr is currently approved in 37 countries worldwide, including the countries of the European Union.

 

Hereditary Angioedema Emerging Drugs

  • Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals

Donidalorsen, formerly known as IONIS-PKK-LRx, is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to target the production of prekallikrein (PKK), which plays an important role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). By reducing the production of PKK, donidalorsen could be an effective prophylactic approach to preventing HAE attacks.

In the phase III OASIS-HAE study, donidalorsen administered subcutaneously every 4 weeks (Q4W) showed an 81% lower mean monthly attack rate compared to placebo over weeks 1 to 25 (p<0.001). The Q8W dosing showed a 55% reduction (p=0.004).

  • Navenibart (STAR-0215): Astria Therapeutics

navenibart (STAR-0215), is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, safe, and effective attack prevention for HAE, with potential for dosing once every 3 and 6 months.

Positive initial proof-of-concept results from the ALPHA-STAR Phase Ib/II clinical trial evaluating navenibart in HAE patients demonstrate a favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, and support both three- (Q3M) and six- month (Q6M) dosing regimens. Based on the positive results, company plan to advance navenibart to Phase III development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.

 

Get In-Depth Knowledge on Hereditary Angioedema Market Trends and Forecasts with DelveInsight @ Hereditary Angioedema Treatment Market

 

Scope of the Hereditary Angioedema Market Report

  • Coverage- 7MM
  • Hereditary Angioedema Companies- KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
  • Hereditary Angioedema Therapies- KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
  • Hereditary Angioedema Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Hereditary Angioedema Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Hereditary Angioedema Market Report @ Hereditary Angioedema Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Hereditary Angioedema (HAE): Market Overview at a Glance

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Treatment of Hereditary Angioedema

7. Epidemiology and Patient Population

8. Marketed Therapies

9. Emerging Therapies

10. Hereditary Angioedema: 7 Major Market Analysis

11. KOL Views

12. SWOT Analysis

13. Unmet Needs

14. Market Access and Reimbursement

15. Appendix

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

Custom Antibody Market Growth, Drivers, and Opportunities – Exclusive Report by MarketsandMarkets™

“Key players in the custom antibody market are Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US)”
Browse 472 market data Tables and 52 Figures spread through 376 Pages and in-depth TOC on “Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) – Global Forecast to 2029

The custom antibody industry is expected to grow significantly in the near future. This growth is largely due to the increasing demand for custom antibodies for research, diagnostics and therapeutic applications. The custom antibody industry has seen an increased demand for antibodies that are specific to a particular target, as well as those that can be used in multiple applications. The industry is expected to continue to expand as more organizations become aware of the potential benefits of custom antibodies. Custom antibodies are also becoming more accessible, due to advances in technology and the development of more efficient processes for producing them. This has allowed companies to manufacture custom antibodies at a much lower cost, making it easier for smaller organizations to access them.

Custom Antibody Market in terms of revenue was estimated to be worth $548 million in 2023 and is poised to reach $860 million by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as rising R&D funding and growing initiatives in custom antibody and increasing use of antibodies in biomarkers & validation are driving the growth of this market. However, challenges associated with the immunization of host animals are the major factors restraining the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164328301

The antibody development segment accounted for the largest share of the service segment in the custom antibody market in 2022.

Based on service, the custom antibody market is broadly segmented into antibody development, antibody production & purification, and antibody labeling. In 2022, antibody development accounted for the largest share of the custom antibody market for service. This segment’s large share can be attributed to factors such as the rising demand for therapeutic antibodies, which are used in a wide range of applications.

The monoclonal antibodies segment accounted for the largest share of the type segment in the custom antibody market in 2022.

Based on type, the custom antibody market is categorized into three segments—monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. In 2022, monoclonal antibodies segment accounted for the largest share of custom antibody market. Factors such as the high degree of sensitivity and precision with the use of monoclonal antibodies in drug discovery and development are projecting the segmental growth.

Asia Pacific is likely to grow at double digit growth rate during the forecast period.

The Asia Pacific region is estimated to grow at the highest CAGR in the custom antibody market during the forecast period, this is mainly due to factors such the rising investment in research & development, increased adoption of custom antibodies for various research and diagnostics purpose, emergence of new market players in custom antibody market.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164328301

Custom Antibody Market Dynamics:

Drivers:

  1. Growing geriatric population and subsequent increase in prevalence of eye disorders
  2. Technological innovations
  3. Growing application areas of Custom Antibody techniques
  4. Growing need to minimize use of radiation technologies

Restraints:

  1. Reimbursement challenges
  2. Lack of skilled operators

Opportunities:

  1. Expansion and market penetration opportunities in emerging economies
  2. Growing applications in pharmaceutical & biotechnology research

Challenges:

  1. Sustainability of small and medium-sized players
  2. High cost of Custom Antibody procedures and extensive data requirements

Key Market Players:

Some of the prominent players in the custom antibody market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies (US), Abcam plc. (UK), Cell Signaling Technology, Inc (US), Bio-Rad Laboratories, Inc (US), GenScript (China), and among others.

Recent Developments

  • In December 2022, Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.
  • In October 2022, Thermo Fisher Scientific acquired The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics.
  • In July 2022, Bio-Techne acquired Namocell to expand its product portfolio, to include gene therapy development and commercialization, cell engineering, cell line development, single cell genomics, and antibody discovery.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=164328301

Custom Antibody Market Advantages:

  • Increased sensitivity: Custom antibodies are specifically designed and tailored to target a specific protein or antigen, ensuring a high level of sensitivity and specificity in the assay.
  • Reduced background noise: Custom antibodies are able to reduce background noise, providing increased signal-to-noise ratios.
  • Cost savings: In comparison to off-the-shelf antibodies, custom antibodies can offer cost savings in terms of both production costs and labor.
  • Improved specificity: Custom antibodies are produced using sophisticated purification techniques, allowing for improved specificity and accuracy.
  • Improved availability: Custom antibodies are available on short lead times, making them a convenient solution for research and development.

Custom Antibody Market- Report Highlights:

Refinement in the segments of the global Custom Antibody market:

  • The current edition of the report consists of an updated market overview, average selling price trends, value chain analysis, Porter’s Five Forces analysis, ecosystem map, pricing analysis, patent analysis, and new industry insights.
  • The report also consists of the impact of recession on the global Custom Antibody market.
  • The competitive landscape chapter has been updated with the market evaluation framework and updated product portfolio matrix. The competitive landscape also includes the revenue share analysis of the top market players and an updated competitive situation and trends section.
  • Competitive leadership mapping for SMEs/start-ups has also been updated for the Custom Antibody market.

Coverage of players in the Custom Antibody market:

  • Pricing analysis, Key conferences, and events 2022-2023, key stakeholders & buying criteria, and trends/ disruptions impacting customer business are added in the market overview chapter.
  • The new edition of the report provides updated financial information till 2021 (depending on availability) for each listed company in a graphical representation. This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment.
  • In the new edition of the report research and therapeutics segment is included under the application segment.
  • In the new edition of the report oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and others segment is included under the indication segment
  • Impact of recession has also been added in the new addition of the report.
  • Recent developments are helpful to understand market trends and growth strategies adopted by players in the market.
  • Tracking product portfolios of prominent market players helps to analyze the major products in the custom antibody market. The new edition of the report provides an updated product portfolio of the companies profiled in the report.
  • Market evaluation framework, market share analysis and competitive leadership mapping have been added in competitive landscape chapter of the report.
  • The competitive leadership mapping has been updated considering recent developments in the company evaluation matrix.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/custom-antibody-market-164328301.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Custom Antibody Market Growth, Drivers, and Opportunities – Exclusive Report by MarketsandMarkets™

Wood Investments Companies Secures $20.3 Million Refinancing for Helena Skyway Regional Shopping Center in Helena, Montana

HELENA, Mont. — Wood Investments Companies, Inc., a leading fully-integrated commercial real estate investment company specializing in retail, has successfully secured a $20.3 million permanent loan from Wells Fargo for the Helena Skyway Regional Shopping Center in Helena, Montana. This 164,121-square-foot shopping center is strategically positioned at a newly developed Interstate 15 Interchange, providing excellent visibility and accessibility.

This financing underscores Wood Investments’ commitment to expanding its portfolio with top-tier properties. “Securing a $20.3 million permanent loan for the Helena Skyway Regional Shopping Center in today’s tight lending environment is a testament to the quality of our property,” said Patrick Wood, CEO and President of Wood Investments Companies. “This achievement not only highlights our commitment to delivering an exceptional retail destination but also reflects the confidence our partners place in our expertise.”

The Helena Skyway Regional Shopping Center is situated at 2005 Cromwell Dixon Lane, directly across from Costco at the intersection of Interstate 15 and East Custer Avenue. Wood Investments acquired the property on September 2, 2022. The center is shadow anchored by The Home Depot and features major tenants such as TJ Maxx, Ulta Beauty, and Hobby Lobby.

As part of its value-add business strategy, Wood Investments has recently signed new leases with Sierra (formerly Sierra Trading Post) and Chick-fil-A. Sierra is set to open on November 9th, while construction for Chick-fil-A is currently underway, with an expected opening at the end of 2025. With these developments, the center is now 100% leased.

Helena, the capital city of Montana, has a population of approximately 34,464, while the broader Helena metropolitan area, which includes Lewis and Clark and Jefferson counties, has a total population of around 96,091. Known for its strong community and economic growth, Helena presents an attractive location for retail investments.

In 2023, Wood Investments secured $39.1 million in permanent loans for two prominent shopping centers in the Boise metropolitan area: Gateway Marketplace and CentrePoint Marketplace, both located in Meridian, Idaho.  

“Wood Investments Companies continues to pursue well-located, value-add development opportunities in the Western U.S., where we can apply our design and tenant influence to create new grocery-anchored neighborhood shopping centers,” Wood noted. “Our strategic approach allows us to transform these properties into vibrant community hubs. We remain dedicated to delivering superior experiences for both tenants and customers while generating positive economic impacts in the communities we serve.”

About Wood Investments Companies, Inc. (WICo)

Established as a premier private family-run enterprise, WICo is a distinguished name in the real estate industry. Headquartered in Newport Beach, California, WICo is owned, operated, and managed by Patrick Wood, who carries forward a legacy of excellence set by his father, the visionary Jim Wood. Jim’s remarkable career includes the development of 60 shopping centers, many of which he still owns today. At WICo Inc., we take pride in being a real estate investment and management firm that excels in acquiring, owning, operating, and developing commercial retail shopping centers, with a strategic focus on value-add redevelopment and investments in the Western United States. Our journey has been enriched by over 60 years of combined experience and success in the retail real estate industry, a testament to our unwavering commitment to excellence. For more information, visit: woodinvestments.com.

Media Contact
Company Name: Wood Investments Companies
Contact Person: Patrick Wood, President/CEO
Email: Send Email
Phone: 657.247.2600 ext. 304
Address:14 Corporate Plaza Suite 120
City: Newport Beach
State: California
Country: United States
Website: https://www.woodinvestments.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wood Investments Companies Secures $20.3 Million Refinancing for Helena Skyway Regional Shopping Center in Helena, Montana

Progressive Multifocal Leukoencephalopathy Treatment Market Size, Drugs, Companies 2024 | DelveInsight

DelveInsight’s “Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Progressive Multifocal Leukoencephalopathy, historical and forecasted epidemiology, as well as the Progressive Multifocal Leukoencephalopathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Progressive Multifocal Leukoencephalopathy Market is an evolving segment of the global healthcare landscape, driven by the increasing Progressive Multifocal Leukoencephalopathy prevalence of the disorder and the continuous development of innovative treatment options. The Progressive Multifocal Leukoencephalopathy Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

 

Discover Key Insights into the Progressive Multifocal Leukoencephalopathy Market with DelveInsight’s In-Depth Report @ Progressive Multifocal Leukoencephalopathy Market Size

 

Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report

  • In October 2024:- National Institute of Neurological Disorders and Stroke (NINDS)- A Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy. Participants will have magnetic resonance imaging (MRI) of the brain. The MRI scanner is a metal cylinder surrounded by a magnetic field. During MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get gadolinium, a contrast agent, through an IV catheter.
  • According to DelveInsight’s epidemiology model, in the US, the total incident cases of PML were approximately 1,687 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by improved diagnostic techniques, along with the aging population.
  • Among EU4 and the UK, Germany accounted for the highest number of incident cases of PML, with approximately 420 cases in 2023, followed by France with approximately 342 cases, and the UK with nearly 339 cases.
  • Among the age-specific incident cases of PML in the US in 2023, the highest cases were observed in the 61–70 years age group with approximately 439 cases whereas the lowest cases were for the 20–30 years of age group with nearly 118 cases.
  • In 2023, Japan accounted for approximately 617 incident cases of PML among the 7MM. These cases are expected to change during the forecast period.
  • In 2023, the etiology-specific categories included hematological malignancies, HIV infection, chemotherapy medications, and autoimmune medications. Notably, HIV infection had the highest number of incident cases, with approximately 352 cases reported in Japan.
  • The leading Progressive Multifocal Leukoencephalopathy Companies such as NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others
  • Promising Progressive Multifocal Leukoencephalopathy Therapies such as NT-I7, CE-VST01-JC, Natalizumab, and others.

 

Stay ahead in the Progressive Multifocal Leukoencephalopathy Therapeutics Market with DelveInsight’s Strategic Report @ Progressive Multifocal Leukoencephalopathy Market Outlook

 

Progressive Multifocal Leukoencephalopathy Epidemiology Segmentation in the 7MM

  • Total Progressive Multifocal Leukoencephalopathy incident cases
  • Progressive Multifocal Leukoencephalopathy age-specific incident cases
  • Progressive Multifocal Leukoencephalopathy etiology-specific incident cases

 

Download the report to understand which factors are driving Progressive Multifocal Leukoencephalopathy epidemiology trends @ Progressive Multifocal Leukoencephalopathy Prevalence

 

Progressive Multifocal Leukoencephalopathy Emerging Drugs

  • NT-I7 Monotherapy (efineptakin alfa): NeoImmuneTech

NT-I7 (efineptakin alfa) represents a significant advancement as the only clinical-stage long-acting human IL-7, targeting oncologic and immunologic applications by enhancing T cell amplification and functionality. IL-7 plays a critical role in the development of naïve and memory T cells and in sustaining immune responses against chronic and foreign antigens. Preliminary clinical trials demonstrate NT-I7’s favorable pharmacokinetic/pharmacodynamic (PK/PD) and safety profiles, both as a standalone treatment and in combination with other anticancer therapies. The drug is currently being evaluated in multiple studies for solid tumors and as a vaccine adjuvant, with plans for additional trials in hematologic malignancies and other immunological indications. Notably, in February 2021, the US FDA cleared an investigational new drug (IND) application for a pilot study assessing NT-I7 in PML, for which it received an Orphan Drug Designation in June 2020.

 

Progressive Multifocal Leukoencephalopathy Treatment Market Landscape

The Progressive Multifocal Leukoencephalopathy treatment landscape primarily includes antiviral agents, immunomodulators, and monoclonal antibodies. Antiviral therapies, such as cidofovir and mefloquine, target the underlying JC virus responsible for PML, though their efficacy remains limited. Immunomodulators, like natalizumab, are pivotal in PML management as they address the immune dysregulation seen in affected patients; however, their use can paradoxically increase PML risk. Additionally, monoclonal antibodies such as rituximab are under investigation for their potential to reconstitute the immune response against opportunistic infections. Collectively, these drug classes highlight the complexity of Progressive Multifocal Leukoencephalopathy treatment, necessitating a nuanced approach that balances antiviral efficacy with immune restoration.

 

Get In-Depth Knowledge on Progressive Multifocal Leukoencephalopathy Market Trends and Forecasts with DelveInsight @ Progressive Multifocal Leukoencephalopathy Treatment Market

 

Progressive Multifocal Leukoencephalopathy Market Outlook

The management of PML currently emphasizes immune restoration to improve survival rates, with antiretroviral therapy and addressing sources of immunosuppression as pivotal components. Despite several agents, including cytosine arabinoside, cidofovir, and mefloquine, being utilized, their effectiveness remains unproven in robust clinical trials. Notably, cytarabine has failed to demonstrate a significant impact on disease progression in randomized studies, while cidofovir has shown mixed results across different patient populations, with survival more closely linked to immune parameters than specific treatments. The emergence of novel therapies, such as NeoImmuneTech’s NT-I7 (efineptakin alfa), highlights a potential shift towards leveraging immune-enhancing strategies. However, the overall pipeline for PML treatments appears underdeveloped, primarily comprising early-phase assets, indicating an urgent need for innovative therapeutic solutions to improve patient outcomes. The prognosis for most PML patients remains grim, underscoring the critical gap in effective treatment options.

 

Progressive Multifocal Leukoencephalopathy Drugs Market

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Progressive Multifocal Leukoencephalopathy Market Report @ Progressive Multifocal Leukoencephalopathy Market Drivers and Barriers

 

Scope of the Progressive Multifocal Leukoencephalopathy Market Report

  • Coverage- 7MM
  • Progressive Multifocal Leukoencephalopathy Companies- NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others
  • Progressive Multifocal Leukoencephalopathy Therapies- NT-I7, CE-VST01-JC, Natalizumab, and others.
  • Progressive Multifocal Leukoencephalopathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Progressive Multifocal Leukoencephalopathy Unmet Needs, KOL’s views, Analyst’s views, Progressive Multifocal Leukoencephalopathy Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Market Overview at a Glance

4 Epidemiology and Market Methodology

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Patient Journey

9 Epidemiology and Patient Population

10 The US

11 Emerging Therapies

12 Progressive Multifocal Leukoencephalopathy: 7 Major Market Analysis

13 SWOT Analysis

14 Unmet Needs

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Progressive Multifocal Leukoencephalopathy Treatment Market Size, Drugs, Companies 2024 | DelveInsight